Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Volume: 383, Issue: 24, Pages: 2345 - 2357
Published: Dec 10, 2020
Abstract
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall...
Paper Details
Title
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Published Date
Dec 10, 2020
Volume
383
Issue
24
Pages
2345 - 2357
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History